Erlotinib (Tablet)


Indications and Reactions:

Role Indications Reactions
Primary
Non-small Cell Lung Cancer 46.5%
Pancreatic Carcinoma Metastatic 13.7%
Pancreatic Carcinoma 9.5%
Neoplasm Malignant 5.8%
Ovarian Cancer 3.8%
Colon Cancer Metastatic 3.5%
Colorectal Cancer 2.4%
Lung Adenocarcinoma 2.0%
Breast Cancer Metastatic 1.8%
Gastrointestinal Carcinoma 1.3%
Glioblastoma Multiforme 1.3%
Laryngeal Cancer 1.3%
Renal Cell Carcinoma Stage Unspecified 1.3%
Hepatic Neoplasm Malignant 0.9%
Metastatic Neoplasm 0.9%
Neoplasm 0.9%
Non-small Cell Lung Cancer Metastatic 0.9%
Tongue Neoplasm Malignant Stage Unspecified 0.9%
Oesophageal Carcinoma 0.7%
Prostate Cancer 0.7%
Vomiting 16.4%
White Blood Cell Count Decreased 14.8%
Pulmonary Embolism 12.3%
Small Intestinal Obstruction 4.9%
Anaemia 4.1%
Pain 4.1%
Sepsis 4.1%
Thrombocytopenia 4.1%
Viral Infection 4.1%
Weight Decreased 4.1%
Pancreatitis Acute 3.3%
Pneumonia 3.3%
Sudden Death 3.3%
Oesophagobronchial Fistula 2.5%
Rectal Haemorrhage 2.5%
Refusal Of Treatment By Patient 2.5%
Respiratory Arrest 2.5%
Respiratory Failure 2.5%
Staphylococcal Infection 2.5%
White Blood Cell Count Increased 2.5%
Secondary
Non-small Cell Lung Cancer 70.6%
Metastatic Neoplasm 23.5%
Glioblastoma Multiforme 5.9%
Pulmonary Embolism 25.0%
Small Intestinal Obstruction 25.0%
Neutropenia 12.5%
Pulmonary Fibrosis 12.5%
Respiratory Failure 12.5%
Visual Acuity Reduced 12.5%

Drug Data